Impact of JAK2V617F mutation on thrombosis and myeloid transformation in essential thrombocythemia: a multivariate analysis by Cox regression in 141 patients

References

• Imbert M, Pierre R, Thiele J, Vardiman JW, Brunning RD, Flandrin G. Essential thrombocythaemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW. (eds). Tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours. Lyon: IARC Press, 2001; 39–41.
   Google Scholar
• Spivak JL, Barosi G, Tognoni G et al. Chronic myeloproliferativedisorders. Hematol Am Soc Hematol Educ Program 2003: 200–224.
   PubMedGoogle Scholar
• Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 inthe pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer 2007; 7: 673–683.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Thiele J, Orazi A et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.
   PubMed Web of Science ®Google Scholar
• Spivak JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis and primary myelofibrosis: an alternative proposal. Blood 2008; 11: 231–239.
   Web of Science ®Google Scholar
• Wolanskyj AP, Lasho TL, Schwager SM et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol 2005; 131: 208–213.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pancrazzi A et al. Clinical implicationsof the JAK2 V617F mutation in essential thrombocythemia. Leukemia 2005; 19: 1847–1849.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Rambaldi A, Guerini V, Carobbo A, Barbui T. Risk ofthrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status. Haematologica 2007; 92: 135–136.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G et al. Definition of subtypes ofessential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945–1953.
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol 2006; 132: 244–245.
   PubMed Web of Science ®Google Scholar
• Ohyashiki K, Ito Y, Hon IK, Sato K, Makino T, Ohyashiki JH. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan. Leukemia 2007; 21: 1570–1571.
   PubMed Web of Science ®Google Scholar
• Hsiao HH, Yang MY, Liu YC et al. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia. Exp Hematol 2007; 35: 1704–1707.
   PubMed Web of Science ®Google Scholar
• Cheuk BL, Cheung GC, Cheng SW. Epidemiology of venous thromboembolism in a Chinese population. Br J Surg 2004; 91: 424–428.
   PubMed Web of Science ®Google Scholar
• Chan YK, Chiu KY, Cheng SW, Ho P. The incidence of deep vein thrombosis in elderly Chinese suffering hip fracture is low without prophylaxis: a prospective study using serial duplex ultrasound. J Orthop Surg (Hong Kong) 2004; 12: 178–183.
   PubMedGoogle Scholar
• Woo KS, Donnan SP. Epidemiology of coronary arterial disease inthe Chinese. Int J Cardiol 1989; 24: 83–93.
   PubMed Web of Science ®Google Scholar
• Bernhardt R, Feng Z, Deng Y et al. Incidence and mortality rates of myocardial infarction in Chinese workers aged 40-59 in relation to coronary risk factors. Results of a Chinese prospective study (Wuhan Study) in comparison to the G8ttingen Risk Incidence and Prevalence Study (GRIPS). Klin Wochenschr 1991; 69: 201–212.
   PubMedGoogle Scholar
• Chan WP, Lee CK, Kwong YL, Lam CK, Liang R. A novel mutation of Arg306 of factor V gene in Hong Kong Chinese. Blood 1998; 91: 1135–1139.
   PubMed Web of Science ®Google Scholar
• Jun ZJ, Ping T, Lei Y, Li L, Ming SY, Jing W. Prevalence of factor V Leiden and prothrombin G20210A mutations in Chinese patients with deep venous thrombosis and pulmonary embolism. Clin Lab Haematol 2006; 28: 111–116.
   PubMedGoogle Scholar
• Michiels JJ, de Raeve H, Berneman Z et al. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative dis-orders. Semin Thromb Hemost 2006; 32 (4 Pt 2): 307–340.
   PubMed Web of Science ®Google Scholar
• Kwong YL, Chiu EK, Liang RH, Chan V, Chan TK. Essential thrombocythemia with BCR/ABL rearrangement. Cancer Genet Cytogenet 1996; 89: 74–76.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J et al. International Working Group for Myelofibrosis Research and Treatment (IWG-MRT). Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 2008; 22: 437–438.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054–1061.
   PubMed Web of Science ®Google Scholar
• Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Soc Statist Series B 1972; 34: 187–220.
   Web of Science ®Google Scholar
• Liu HW, Kwong YL, Bourke C et al. High incidence of thrombophilia detected in Chinese patients with venous thrombo-sis. Thromb Haemost 1994; 71: 416–419.
   PubMed Web of Science ®Google Scholar
• Chim CS, Kwong YL, Lie AK et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005; 165: 2651–2618.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007; 109: 2310–2313.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Antonioli E, Guglielmelli P et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol 2008; 26: 2732–2736.
   PubMed Web of Science ®Google Scholar
• Ziakas PD. Effect of JAK2 V617F on thrombotic risk in patients with essential thrombocythemia: measuring the uncertain. Haematologica 2008; 93: 1412–1414.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Poli G et al. Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica 2008; 93: 41–48.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702–711.
   PubMed Web of Science ®Google Scholar